Are AnteoTech (ASX:ADO) rapid COVID tests available in Australia?

The company's rapid testing device still isn't able to be used in Australia.

| More on:
a woman inserts a swab up her nostril while conducting a rapid antigen test for COVID-19 in her home.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The AnteoTech Ltd (ASX: ADO) share price has soared since the start of the pandemic as the company has worked to create a COVID-19 rapid antigen test.

Enthusiasm surrounding the now-developed point-of-care rapid testing device has helped boost the company's stock by more than 1000% since the start of 2020.

AnteoTech's EuGeni testing device is now reportedly widely used in the United States and Europe. However, the Queensland-based company's test is facing ongoing delays for Australian approvals, much to the frustration of AnteoTech's boss.

At the time of writing, the AnteoTech share price is 31.5 cents, 3.28% higher than its previous close.

For context, the S&P/ASX 200 Index (ASX:XJO) is up 0.86% right now.

Is the AnteoTech COVID rapid test locked in TGA delays?

AnteoTech's calls for more rapid testing have been answered, but the company's product still can't be found in Australia.

AnteoTech CEO Derek Thomson reportedly told Queensland's The Courier Mail, the company pushed the state government to accept rapid tests as a measure to screen for the virus. Last week, the publication quoted Thomson as saying:

We've always said that rapid testing has a place to be used to control the pandemic and now we're seeing that play out…

There's too much stress on the PCR testing system in all Australian states and it's really not necessary to go to the full extent of doing a PCR test when you've got rapid tests readily available now.

Days after Thomson's comments, Queensland Premier Annastacia Palaszczuk declared the state would allow arriving travellers' entry after they receive a negative rapid test. Previously, arrivals had to receive a negative PCR test.

Further, Palaszczuk announced close contacts in Queensland will soon be given access to 18 million free rapid antigen tests at COVID-19 testing sites yesterday, saying:

We know the transition to RAT tests for close contacts will reduce some of the pressure we have seen at testing clinics in recent weeks, ensuring those with symptoms can be tested sooner.

Still, Thomson reportedly noted it's "quite frustrating" the Therapeutic Goods Administration hasn't approved the use of the AnteoTech's COVID-19 rapid antigen test.

That's despite the potential its approval could lead to millions more 15-minute tests being made available to Australians. The EuGeni testing device has been proven to be accurate 97.3% of the time.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A man sits in contemplation on his sofa looking at his phone as though he has just heard some serious or interesting news.
Technology Shares

Up 60% in two months, is it too late to buy Pro Medicus shares?

Pro Medicus has been delivering solid returns for years. Can the trend continue?

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why this ASX All Ords stock is jumping 9% today

What has put a rocket under this stock on Friday? Let's find out.

Read more »

A hipster dude leaps in the air with glee, seeing positive news on his tablet.
Healthcare Shares

Which ASX 200 stock is jumping 11% on big news?

Investors are responding very positively to a big announcement.

Read more »

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Healthcare Shares

Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell?

ResMed shares have surged more than 75% since October 2023, but is it too late to buy? We break down…

Read more »

Stethoscope with a piggy bank in the middle.
Broker Notes

Australian health insurance: Does Macquarie prefer Medibank or NIB shares?

Medibank and NIB shares have both surged in 2025. Here’s what Macquarie expects now.

Read more »

Two brokers analysing stocks.
Healthcare Shares

Why does Macquarie think Fisher & Paykel shares are a buy?

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) shares have been on form over the past 12 months. During this…

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Which small cap ASX share is jumping 10% on strong results

Investors have been bidding this stock higher today. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why Macquarie forecasts 30-50% upside for these ASX All Ords healthcare stocks

Macquarie updated its target price on these three ASX All Ords healthcare stocks.

Read more »